Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis

References

• Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39:237–246.
   PubMed Web of Science ®Google Scholar
• Qu H, Li J, Wu L, et al. Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease. Mol Med Rep.2016;14: 2423–2430.
   PubMed Web of Science ®Google Scholar
• Steenvoorden MM, Huizinga TW, Verzijl N, et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum. 2006;54:253–263.
   PubMed Web of Science ®Google Scholar
• Sun ZJ, Xia YY. Autophagy plays a protective role in advanced glycation end products-induced apoptosis of chondrocytes via regulation of tumor necrosis factor-α, nuclear factor-κ B and reactive oxygen species. Asian Pac J Trop Med. 2018;11:73.
   Web of Science ®Google Scholar
• Forbes JM, Cooper ME, Oldfield MD, et al. 2003. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S254–S258.
   PubMed Web of Science ®Google Scholar
• Collins JA, Wood ST, Poole L, et al. The level of reactive oxygen species differentially regulates peroxiredoxin oxidation and mitogen-activated protein kinase signaling in human chondrocytes. Osteoarthritis Cartilage. 2016;24:S179–S180.
   Web of Science ®Google Scholar
• Tchkonia T, Zhu Y, Van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966–972.
   PubMed Web of Science ®Google Scholar
• Huang CY, Lai KY, Hung LF, et al. Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes. Rheumatology (Oxford). 2011;50:1379–1389.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42.
   PubMed Web of Science ®Google Scholar
• Poole AR, Kobayashi M, Yasuda T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis. 2002;61:ii78–ii81.
   PubMed Web of Science ®Google Scholar
• Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157–164.
   PubMedGoogle Scholar
• Neuhold LA, Killar L, Zhao W, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J CLIN Invest. 2001;107:35–44.
   PubMed Web of Science ®Google Scholar
• Echtermeyer F, Bertrand J, Dreier R, et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med. 2009;15:1072–1076.
   PubMed Web of Science ®Google Scholar
• Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem. 2011;112:3507–3514.
   PubMed Web of Science ®Google Scholar
• Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. CDT. 2009;10:42–50.
   Web of Science ®Google Scholar
• Leong DJ, Sun HB. Events in articular chondrocytes with aging. Curr Osteoporos Rep. 2011;9:196.
   PubMedGoogle Scholar
• Qin YH, Dai SM, Tang GS, et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol. 2009;183:6244–6250.
   PubMed Web of Science ®Google Scholar
• Traynor K. FDA approves saxagliptin for type 2 diabetes. Am J Health Syst Pharm. 2009;66:1513.
   Web of Science ®Google Scholar
• Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf. 2016;39:401–407.
   PubMed Web of Science ®Google Scholar
• Iepsen EW, Lundgren JR, Hartmann B, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100:2909–2917.
   PubMed Web of Science ®Google Scholar
• Roth JD, Erickson MR, Chen S, et al. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol. 2012;166:121–136.
   PubMed Web of Science ®Google Scholar
• Chen J, Xie JJ, Shi KS, et al. Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis. 2018;9:212.
   PubMed Web of Science ®Google Scholar
• Capsoni F, Ongari AM, Lonati C, et al. α-Melanocyte-stimulating-hormone (α-MSH) modulates human chondrocyte activation induced by proinflammatory cytokines. BMC Musculoskelet Disord. 2015;16:154.
   PubMed Web of Science ®Google Scholar
• Mahmoud RK, El-Ansary AK, El-Eishi HH. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem 2005;54:248–257.
   PubMedGoogle Scholar
• Goldring MB, Otero M, Plumb DA, et al. Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis. ECM. 2011;21:202–220.
   Web of Science ®Google Scholar
• Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5:194–222.
   PubMed Web of Science ®Google Scholar
• Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 2007;56:575–585.
   PubMed Web of Science ®Google Scholar
• Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–429.
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Rev Endocrinol. 2008;4:285–293.
   Web of Science ®Google Scholar
• Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773:1358–1375.
   PubMed Web of Science ®Google Scholar
• Olivotto E, Otero M, Marcu KB, et al. Pathophysiology of osteoarthritis: canonical NF-κB/IKKβ-dependent and kinase-independent effects of IKKα in cartilage degradation and chondrocyte differentiation. RMD Open. 2015;1:e000061.
   PubMed Web of Science ®Google Scholar
• Mohetaer M, Li G, Wang Y, et al. Protective effects of gemigliptin against type II collagen degradation in human chondrocytes. Biomed Pharmacother. 2018;104:590–594.
   PubMed Web of Science ®Google Scholar
• Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun N-terminal kinase, and nuclear factor κB: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000;43:801–811.
   PubMed Web of Science ®Google Scholar
• Zandi E, Rothwarf DM, Delhase M, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91:243–252.
   PubMed Web of Science ®Google Scholar